Marketdash
Back to News

Vistagen Shares Crater Nearly 80% After Anxiety Drug Flops in Late-Stage Trial

MarketDash Editorial Team
2 hours ago
Vistagen's experimental social anxiety treatment fasedienol failed its Phase 3 trial, missing the primary endpoint despite earlier promising results. The stock plummeted to a new 52-week low as trading volume surged 29-fold.

When your late-stage drug trial fails spectacularly, the market doesn't waste time asking questions. Vistagen Inc. (VTGN) learned this harsh lesson Wednesday as shares nosedived nearly 80% following disappointing results from its pivotal anxiety treatment study.

The clinical-stage biopharmaceutical company announced that PALISADE-3, its Phase 3 trial evaluating intranasal fasedienol for acute treatment of social anxiety disorder, missed the mark entirely. The study failed to achieve its primary endpoint, a gut punch for a company betting heavily on this program.

Here's what happened: PALISADE-3 tested whether a single dose of fasedienol could help people manage anxiety during a simulated public speaking challenge. Researchers measured effectiveness using the Subjective Units of Distress Scale (SUDS), a standard metric for quantifying anxiety symptoms. The trial didn't show statistically significant improvement on that primary measure. Worse, fasedienol showed no treatment difference versus placebo across secondary endpoints either.

The silver lining? Safety data remained favorable and consistent with previous clinical trials. But when your drug doesn't actually work better than placebo, good safety is cold comfort.

"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our PALISADE-2 Phase 3 study," said Shawn Singh, president and CEO of Vistagen. The company is now thoroughly reviewing the study results, evaluating the potential impact on ongoing studies, and plans to seek feedback from the FDA.

That inconsistency with earlier positive data makes this particularly puzzling. Phase 2 looked promising. The PALISADE-2 Phase 3 study showed positive outcomes. Then PALISADE-3 faceplanted. Understanding why will be critical for Vistagen's path forward.

The market reaction was swift and brutal. Trading volume exploded to 20.91 million shares compared to the average volume of 711,000, according to market data. Shares plummeted to $0.89, hitting a new 52-week low.

Vistagen has moved quickly to implement cash preservation measures, aiming to enhance operational efficiency and extend its cash runway into 2027. That's startup-speak for "we're cutting costs to survive long enough to figure out what's next."

Back to News

Vistagen Shares Crater Nearly 80% After Anxiety Drug Flops in Late-Stage Trial

MarketDash Editorial Team
2 hours ago
Vistagen's experimental social anxiety treatment fasedienol failed its Phase 3 trial, missing the primary endpoint despite earlier promising results. The stock plummeted to a new 52-week low as trading volume surged 29-fold.

When your late-stage drug trial fails spectacularly, the market doesn't waste time asking questions. Vistagen Inc. (VTGN) learned this harsh lesson Wednesday as shares nosedived nearly 80% following disappointing results from its pivotal anxiety treatment study.

The clinical-stage biopharmaceutical company announced that PALISADE-3, its Phase 3 trial evaluating intranasal fasedienol for acute treatment of social anxiety disorder, missed the mark entirely. The study failed to achieve its primary endpoint, a gut punch for a company betting heavily on this program.

Here's what happened: PALISADE-3 tested whether a single dose of fasedienol could help people manage anxiety during a simulated public speaking challenge. Researchers measured effectiveness using the Subjective Units of Distress Scale (SUDS), a standard metric for quantifying anxiety symptoms. The trial didn't show statistically significant improvement on that primary measure. Worse, fasedienol showed no treatment difference versus placebo across secondary endpoints either.

The silver lining? Safety data remained favorable and consistent with previous clinical trials. But when your drug doesn't actually work better than placebo, good safety is cold comfort.

"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our PALISADE-2 Phase 3 study," said Shawn Singh, president and CEO of Vistagen. The company is now thoroughly reviewing the study results, evaluating the potential impact on ongoing studies, and plans to seek feedback from the FDA.

That inconsistency with earlier positive data makes this particularly puzzling. Phase 2 looked promising. The PALISADE-2 Phase 3 study showed positive outcomes. Then PALISADE-3 faceplanted. Understanding why will be critical for Vistagen's path forward.

The market reaction was swift and brutal. Trading volume exploded to 20.91 million shares compared to the average volume of 711,000, according to market data. Shares plummeted to $0.89, hitting a new 52-week low.

Vistagen has moved quickly to implement cash preservation measures, aiming to enhance operational efficiency and extend its cash runway into 2027. That's startup-speak for "we're cutting costs to survive long enough to figure out what's next."